- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | Engene Holdings stock rating maintained at Market Perform by Citizens | 5 | Investing.com | ||
| 08.09. | enGene auf Wells-Fargo-Konferenz: Entwicklung von Blasenkrebstherapie im Fokus | 3 | Investing.com Deutsch | ||
| 08.09. | EnGene Therapeutics Inc. Earnings At $32.50 Mln In Q3 | 1 | RTTNews | ||
| 08.09. | enGene Holdings GAAP EPS of -$0.47 misses by $0.04 | 1 | Seeking Alpha | ||
| 08.09. | enGene Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.09. | enGene Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.07. | enGene Appoints Michael Heffernan As Board Chairman Ahead Of Planned BLA Filing For Bladder Cancer Therapy | 2 | pulse2.com | ||
| 16.07. | enGene appoints Michael Heffernan as board chairman | 1 | Investing.com | ||
| ENGENE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 16.07. | enGene: Michael Heffernan übernimmt Vorsitz des Verwaltungsrats | 1 | Investing.com Deutsch | ||
| 16.07. | enGene Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.06. | Morgan Stanley cuts Engene stock rating on reduced sales outlook | 2 | Investing.com | ||
| 18.06. | Engene: Morgan Stanley senkt Rating wegen schwächerer Umsatzaussichten | 2 | Investing.com Deutsch | ||
| 16.06. | Neumora depression drug fails; EnGene to cut 50% of staff | 4 | BioPharma Dive | ||
| 16.06. | H.C. Wainwright cuts Engene stock price target on clinical setbacks | 1 | Investing.com | ||
| 15.06. | enGene Holdings GAAP EPS of $0.43 | 1 | Seeking Alpha | ||
| 15.06. | enGene Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 10.06. | enGene Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Analysts cut enGene cancer sales forecast after updated data widen gap to J&J | 13 | FierceBiotech | ||
| 08.05. | Citizens downgrades Engene Holdings stock rating on weaker trial data | 2 | Investing.com | ||
| 08.05. | Citizens stuft Engene Holdings-Aktie nach schwachen Studiendaten ab | 19 | Investing.com Deutsch |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 84,75 | +1,32 % | BioNTech-Aktie: Sind jetzt wirklich über +40% drin? | Die BioNTech-Aktie kämpft diese Woche mit der Kursmarke von 85 €. Verkennt die Börse das Potenzial des deutschen Biotech-Unternehmens? Zwei gute Nachrichten Obwohl BioNTech in den letzten Tagen gleich... ► Artikel lesen | |
| AMGEN | 337,25 | +0,46 % | Amgen: FDA Approves Update To IMDELLTRA Prescribing Information, Cuts Monitoring Time For Two Doses | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the FDA approved an update to the IMDELLTRA Prescribing Information that substantially reduces the recommended monitoring time for the first... ► Artikel lesen | |
| NOVAVAX | 8,900 | +1,25 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| BIOGEN | 189,52 | +0,99 % | Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN | EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 10,900 | 0,00 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,058 | -1,76 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,550 | +1,19 % | Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. | ||
| INFLARX | 1,790 | -1,86 % | InflaRx N.V.: InflaRx to Host Virtual Capital Markets Day | ||
| INTELLIA THERAPEUTICS | 10,720 | +1,32 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 68,12 | +0,53 % | Goldman Sachs startet Coverage für Tempus AI Aktie mit "Neutral"-Rating | ||
| EDITAS MEDICINE | 2,370 | +0,85 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,540 | +0,67 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,398 | +0,51 % | Breaking News: Weiche zur Nasdaq gestellt | ||
| ABIVAX | 91,75 | -2,89 % | Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call | ||
| BIOMARIN PHARMACEUTICAL | 55,74 | +0,14 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors | SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D.... ► Artikel lesen |
ENGENE THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,020 (+1,29 %) liegt der Kurs bei 1,566 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENGENE THERAPEUTICS INC finden Sie auf Wallstreet Online.